Li Peiyao, Feng Jianbo, Liu Yang, Liu Qiang, Fan Li, Liu Qing, She Xiaoling, Liu Changhong, Liu Tao, Zhao Chunhua, Wang Wei, Li Guiyuan, Wu Minghua
Hunan Provincial Tumor Hospital and the Affiliated Tumor Hospital of Xiangya Medical School, Central South University, Changsha, China.
Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Key Laboratory of Carcinogenesis, Ministry of Health, Cancer Research Institute, Central South University, Changsha, China.
Front Immunol. 2017 Dec 11;8:1748. doi: 10.3389/fimmu.2017.01748. eCollection 2017.
Glioblastoma multiforme (GBM) is a heterogeneous malignant brain tumor, the pathological incidence of which induces the accumulation of tumor-infiltrating lymphocytes (TILs). As a tumor suppressor gene, LRRC4 is absent in GBM cells. Here, we report that the recovery of LRRC4 in GBM cells inhibited the infiltration of tumor-infiltrating regulatory T cells (Ti-Treg), promoted the expansion of tumor-infiltrating effector T (Ti-Teff) cells and CD4CCR4 T cells, and enhanced the chemotaxis of CD4CCR4 T cells in the GBM immune microenvironment. LRRC4 was not transferred into TILs from GBM cells through exosomes but mainly exerted its inhibiting function on Ti-Treg cell expansion by directly promoting cytokine secretion. GBM cell-derived exosomes (cytokine-free and programmed cell death 1 containing) also contributed to the modulation of LRRC4 on Ti-Treg, Ti-Teff, and CD4CCR4 T cells. In GBM cells, LRRC4 directly bound to phosphoinositide-dependent protein kinase 1 (PDPK1), phosphorylated IKKβser181, facilitated NF-κB activation, and promoted the secretion of interleukin-6 (IL-6), CCL2, and interferon gamma. In addition, HSP90 was required to maintain the interaction between LRRC4 and PDPK1. However, the inhibition of Ti-Treg cell expansion and promotion of CD4CCR4 T cell chemotaxis by LRRC4 could be blocked by anti-IL-6 antibody or anti-CCL2 antibody, respectively. miR-101 is a suppressor gene in GBM. Our previous studies have shown that EZH2, EED, and DNMT3A are direct targets of miR-101. Here, we showed that miR-101 reversed the hypermethylation of the LRRC4 promoter and induced the re-expression of LRRC4 in GBM cells by directly targeting EZH2, EED, and DNMT3A. Our results reveal a novel mechanism underlying GBM microenvironment and provide a new therapeutic strategy using re-expression of LRRC4 in GBM cells to create a permissive intratumoral environment.
多形性胶质母细胞瘤(GBM)是一种异质性恶性脑肿瘤,其病理发生率会导致肿瘤浸润淋巴细胞(TILs)的积累。作为一种肿瘤抑制基因,LRRC4在GBM细胞中缺失。在此,我们报告GBM细胞中LRRC4的恢复抑制了肿瘤浸润调节性T细胞(Ti-Treg)的浸润,促进了肿瘤浸润效应T(Ti-Teff)细胞和CD4CCR4 T细胞的扩增,并增强了GBM免疫微环境中CD4CCR4 T细胞的趋化性。LRRC4不是通过外泌体从GBM细胞转移到TILs中,而是主要通过直接促进细胞因子分泌对Ti-Treg细胞扩增发挥抑制作用。GBM细胞来源的外泌体(不含细胞因子且含有程序性细胞死亡1)也有助于LRRC4对Ti-Treg、Ti-Teff和CD4CCR4 T细胞的调节。在GBM细胞中,LRRC4直接与磷酸肌醇依赖性蛋白激酶1(PDPK1)结合,使IKKβser181磷酸化,促进NF-κB激活,并促进白细胞介素-6(IL-6)、CCL2和干扰素γ的分泌。此外,HSP90是维持LRRC4与PDPK1之间相互作用所必需的。然而,LRRC4对Ti-Treg细胞扩增的抑制和对CD4CCR4 T细胞趋化性的促进分别可被抗IL-6抗体或抗CCL2抗体阻断。miR-101是GBM中的一个抑制基因。我们之前的研究表明,EZH2、EED和DNMT3A是miR-101的直接靶点。在此,我们表明miR-101通过直接靶向EZH2、EED和DNMT3A逆转了LRRC4启动子的高甲基化,并诱导GBM细胞中LRRC4的重新表达。我们的结果揭示了GBM微环境的一种新机制,并提供了一种新的治疗策略,即通过在GBM细胞中重新表达LRRC4来创造一个有利的肿瘤内环境。